Business UpdateJun 17, 2026, 04:37 PM
Lunai Bioworks Secures First Defense Contract, Pursues Short Selling Litigation
AI Summary
Lunai Bioworks Inc. issued a letter to shareholders detailing significant strategic advancements and legal action. The company secured its first revenue-generating, multi-year defense collaboration for AI-enabled chemical threat assessment and established the Pathfinder Consortium with leading academic institutions. Concurrently, Lunai is advancing its precision neurology pipeline and has initiated legal action against alleged naked short sellers, with the court granting expedited discovery to identify responsible parties and restore shareholder value.
Key Highlights
- Secured first revenue-generating, multi-year defense collaboration for AI-enabled chemical threat assessment.
- Established Pathfinder Consortium with Harvard, Brigham and Women’s, Utah, Purdue, and Colorado Universities.
- Advancing precision neurology pipeline in Epilepsy, Parkinson's, and Alzheimer's with Augusta™ AI platform.
- Received NIH-supported Phase I/II STTR grant of $1.85 million for alcohol use disorder research.
- Initiated legal action in May 2026 against alleged naked short sellers in U.S. District Court, Delaware.
- Court granted expedited discovery, citing anomalous failing-to-deliver of 29.6 million shares (81.6% of outstanding).
- Peak trading volumes on March 17, 2026, reached 554 million shares, 15.3 times all outstanding shares.
Price Impact
More from LNAI